Walter Alexander


Authored Items

Once-Weekly Carfilzomib for Patients with Relapsed or Refractory Multiple Myeloma Improves Progression-Free Survival

August 2018, Vol 8, No 8 - 2018 EHA Congress Highlights

Once-weekly carfilzomib (Kyprolis) therapy at a higher dose significantly improved progression-free survival (PFS) and reduced the risk of disease progression or death compared with twice-weekly carfilzomib in patients with relapsed or refractory multiple myeloma. The overall safety profile for both regimens in the randomized phase 3 ARROW clinical trial were similar, said co-lead investigator María-Victoria Mateos, MD, PhD, Director, Myeloma Unit, University Hospital Salamanca-IBSAL, Spain, at the 2018 European Hematology Association Congress. [ Read More ]

Immunotherapy with Nivolumab plus Ipilimumab Improves Outcomes in Metastatic Urothelial Cancer

March 2017, Vol 7, No 3 - Immunotherapy

Results of a phase 1/2 study that investigated 2 dosing regi­-mens of 2 immunotherapies—the PD-1 inhibitor nivolumab (Opdivo) plus the CTLA-4 inhibitor ipilimumab (Yervoy)—in patients with previously treated metastatic urothelial carcinoma showed higher response rates and longer median overall survival with the regimen of nivolumab 1 mg/kg plus ipilimumab 3 mg/kg than with the dosing of nivolumab 3 mg/kg plus ipilimumab 1 mg/kg. [ Read More ]